| Product Code: ETC7642769 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview |
3.1 Ireland Country Macro Economic Indicators |
3.2 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, 2021 & 2031F |
3.3 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market - Industry Life Cycle |
3.4 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market - Porter's Five Forces |
3.5 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.6 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.7 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.8 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness and acceptance of vasomotor menopausal symptoms (VMS) treatment options in Ireland |
4.2.2 Growing aging population leading to a higher prevalence of menopausal symptoms |
4.2.3 Technological advancements in treatment options for VMS in Ireland |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for approval of VMS treatment options in Ireland |
4.3.2 Limited availability of specialized healthcare professionals for VMS treatment |
4.3.3 High cost associated with VMS treatment options in Ireland |
5 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Trends |
6 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market, By Types |
6.1 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market, By Drug Class |
6.1.1 Overview and Analysis |
6.1.2 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Drug Class, 2021- 2031F |
6.1.3 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Antidepressants, 2021- 2031F |
6.1.4 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Fluoxetine, 2021- 2031F |
6.1.5 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Paroxetine, 2021- 2031F |
6.1.6 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Sertraline, 2021- 2031F |
6.1.7 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Hormone Therapy, 2021- 2031F |
6.1.8 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Anticonvulsant, 2021- 2031F |
6.1.9 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Phenobarbital, 2021- 2031F |
6.1.10 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Phenobarbital, 2021- 2031F |
6.2 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market, By Route of Administration |
6.2.1 Overview and Analysis |
6.2.2 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Oral, 2021- 2031F |
6.2.3 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.2.4 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market, By End-Users |
6.3.1 Overview and Analysis |
6.3.2 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.3.3 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.3.4 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Homecare, 2021- 2031F |
6.3.5 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market, By Distribution Channel |
6.4.1 Overview and Analysis |
6.4.2 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.4.3 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.4.4 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.4.5 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Others, 2021- 2031F |
7 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Import-Export Trade Statistics |
7.1 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Export to Major Countries |
7.2 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Imports from Major Countries |
8 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Key Performance Indicators |
8.1 Number of clinical trials conducted for VMS treatment options in Ireland |
8.2 Adoption rate of new VMS treatment technologies in Ireland |
8.3 Patient satisfaction and improvement in quality of life post-treatment for VMS in Ireland |
9 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market - Opportunity Assessment |
9.1 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.2 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.3 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.4 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market - Competitive Landscape |
10.1 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenue Share, By Companies, 2024 |
10.2 Ireland Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here